Delcath Systems, Inc. (NASDAQ:DCTH) Shares Purchased by Diametric Capital LP

Diametric Capital LP lifted its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 39.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 94,737 shares of the company's stock after purchasing an additional 26,881 shares during the quarter. Delcath Systems comprises about 0.8% of Diametric Capital LP's investment portfolio, making the stock its 27th largest position. Diametric Capital LP owned approximately 0.30% of Delcath Systems worth $1,141,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in DCTH. Quantbot Technologies LP acquired a new position in Delcath Systems during the fourth quarter worth about $66,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $102,000. Barclays PLC acquired a new stake in shares of Delcath Systems in the 3rd quarter worth approximately $104,000. Jane Street Group LLC purchased a new position in Delcath Systems in the 3rd quarter valued at approximately $110,000. Finally, Private Advisor Group LLC acquired a new position in Delcath Systems during the fourth quarter worth $153,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Trading Down 8.3 %

Shares of NASDAQ:DCTH traded down $0.99 on Friday, hitting $11.01. The company had a trading volume of 642,275 shares, compared to its average volume of 345,504. The company has a market cap of $367.77 million, a PE ratio of -8.16 and a beta of 0.85. The business has a 50 day moving average of $14.28 and a 200 day moving average of $12.12. Delcath Systems, Inc. has a 52-week low of $4.26 and a 52-week high of $16.97.

Remove Ads

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same period in the prior year, the business earned ($0.48) earnings per share. As a group, equities analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Craig Hallum upped their target price on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a report on Friday, January 17th. HC Wainwright raised their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Delcath Systems presently has an average rating of "Moderate Buy" and an average target price of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.